Humoral immune responses to peptides derived from the beta-amyloid peptide C-terminal sequence (Q48191411)

9 February 2018

title

Humoral immune responses to peptides derived from the beta-amyloid peptide C-terminal sequence (English)

1 reference

9 February 2018

1

David L Miller

1 reference

9 February 2018

author name string

Anna Potempska

series ordinal

2

1 reference

9 February 2018

Pankaj D Mehta

series ordinal

3

1 reference

9 February 2018

publication date

1 March 2007

1 reference

9 February 2018

published in

Amyloid

1 reference

9 February 2018

volume

14

1 reference

9 February 2018

issue

1

1 reference

9 February 2018

page(s)

39-50

1 reference

9 February 2018

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

cites work

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

Soluble amyloid beta-protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementia and controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

[10] Reductive cleavage of cystine disulfides with tributylphosphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

Quantification of sub-femtomole amounts of Alzheimer amyloid beta peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

Effects of chronic glucocorticoid administration on insulin-degrading enzyme and amyloid-beta peptide in the aged macaque.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

Elevation in plasma Abeta42 in geriatric depression: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

Thiazolidine Formation as a General and Site-Specific Conjugation Method for Synthetic Peptides and Proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13506120601116500

10.1080/13506120601116500

21 January 2018

Identifiers

DOI

1 reference

9 February 2018

1 reference

9 February 2018